+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 65Years
All Genders
ID06860984

Assessing Duloxetine to Prevent Pancreatitis After ERCP in Biliary Disease Patients

Led by Tanta University · Updated on 2026-08-18

44

Participants Needed

1

Research Sites

2 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the safety and effectiveness of duloxetine in preventing pancreatitis that can occur after an endoscopic retrograde cholangiopancreatography ERCP procedure. ERCP is an important tool used to diagnose and treat pancreato-biliary diseases, but it carries a risk of post-ERCP pancreatitis PEP, which is a serious complication causing significant illness and sometimes death. The study compares two groups one receiving a placebo capsule and the other receiving 60 mg of duloxetine, both given 2 hours before the ERCP procedure. Duloxetine is a drug known for managing neuropathic pain with central and peripheral analgesic effects. Participants are randomly assigned to either group in a double-blind manner, meaning neither they nor the researchers know which treatment they receive. Participants will be monitored closely, with the main outcome being whether pancreatitis develops within 24 hours after the ERCP procedure. Blood tests such as amylase and lipase levels will be checked before ERCP to ensure normal levels. The trial lasts until the primary outcome is assessed shortly after the procedure, and safety will be observed during the study period. The entire trial is expected to complete by July 2027.

CONDITIONS

Brief Title

Evaluating the Safety and Efficacy of Duloxetine in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here